Trial Profile
A Phase 3, Randomized, Double-Blind, Cross-Over, Active-Controlled Study of the Efficacy and Safety of HPN-100, Glyceryl Tri-(4-phenylbutyrate), for the Treatment of Adults With Urea Cycle Disorders (Help UCD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Glycerol phenylbutyrate (Primary)
- Indications Hyperammonaemia
- Focus Pharmacokinetics; Registrational
- Acronyms Help UCD
- Sponsors Hyperion Therapeutics
- 30 Nov 2015 According to Horizon Pharma media release, the European Commission has approved glycerol phenylbutyrate oral liquid (RAVICTI) for treatment of urea cycle disorders in patients two months of age and older.
- 27 Jun 2014 New trial record